An April 10 Manhattan Moment op-ed by Jared Meyer indicated that the Food and Drug Administration has inappropriately delayed access to and approval of a serogroup B meningococcal (or MenB) vaccine in the United States.
This assertion is false. FDA is committed both to responding rapidly to public health threats and to approving products for serious medical conditions in a timely manner.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.